ScoreWhy is Rani Therapeutics Holdings, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 16.22% and Operating profit at -210.86% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -25.70
2
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -22.60%, its profits have risen by 22.8%
3
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -22.60% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Rani Therapeutics Holdings, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Rani Therapeutics Holdings, Inc.
-19.9%
-0.22
283.87%
S&P 500
13.22%
0.61
20.17%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
16.22%
EBIT Growth (5y)
-210.86%
EBIT to Interest (avg)
-25.70
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.93
Sales to Capital Employed (avg)
0.06
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
20.93%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-10.54
EV to EBIT
-0.80
EV to EBITDA
-0.82
EV to Capital Employed
13.44
EV to Sales
31.76
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1677.12%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend19What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -31.01 MM
NET PROFIT(HY)
Higher at USD -13.96 MM
ROCE(HY)
Highest at 0%
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
NET SALES(9M)
Higher at USD 1.2 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -195.53 %
DEBTORS TURNOVER RATIO(HY)
Highest at 20.34 times
OPERATING PROFIT(Q)
Highest at USD -10.27 MM
PRE-TAX PROFIT(Q)
Highest at USD -11.22 MM
EPS(Q)
Highest at USD -0.18
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Rani Therapeutics Holdings, Inc.
Net Sales
At USD 1.2 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -31.01 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
Higher at USD -13.96 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Profit
Highest at USD -10.27 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -11.22 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
EPS
Highest at USD -0.18
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -195.53 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 20.34 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
Higher at USD 1.2 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
